Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Operating Income : $-17.87 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Coeptis Therapeutics Holdings Operating Income?

Coeptis Therapeutics Holdings's Operating Income for the three months ended in Mar. 2024 was $-2.92 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-17.87 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Coeptis Therapeutics Holdings's Operating Income for the three months ended in Mar. 2024 was $-2.92 Mil. Coeptis Therapeutics Holdings's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Coeptis Therapeutics Holdings's Operating Margin % for the quarter that ended in Mar. 2024 was %.

Coeptis Therapeutics Holdings's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Coeptis Therapeutics Holdings's annualized ROC % for the quarter that ended in Mar. 2024 was -214.34%. Coeptis Therapeutics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -10,721.53%.

Coeptis Therapeutics Holdings Operating Income Historical Data

The historical data trend for Coeptis Therapeutics Holdings's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coeptis Therapeutics Holdings Operating Income Chart

Coeptis Therapeutics Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Operating Income

-6.71

-14.05

-34.20

-21.49

Coeptis Therapeutics Holdings Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Income	Get a 7-Day Free Trial									-6.54	-3.69	-7.90	-3.37	-2.92

Coeptis Therapeutics Holdings Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.87 Mil.

Coeptis Therapeutics Holdings (NAS:COEP) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Coeptis Therapeutics Holdings's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-11.688 * ( 1 - 0% )	/	( (4.626	+	6.28)	/ 2 )
=	-11.688	/	5.453
=	-214.34 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.071	-	1.976	-	( 1.469	-	max(0, 2.989	-	5.25	+	1.469	))
=	4.626

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	9.394	-	2.085	-	( 1.029	-	max(0, 4.301	-	6.88	+	1.029	))
=	6.28

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Coeptis Therapeutics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-11.204	/	( ( (0.109 + max(-1.734, 0))	+	(0.1 + max(-1.843, 0)) )	/	2 )
=	-11.204	/	( ( 0.109	+	0.1 )	/	2 )
=	-11.204	/	0.1045
=	-10,721.53 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.242)	-	(1.976	+	0	+	0)
=	-1.734

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.242)	-	(2.085	+	0	+	0)
=	-1.843

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Coeptis Therapeutics Holdings's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %	=	Operating Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-2.922	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Coeptis Therapeutics Holdings Operating Income Related Terms

Thank you for viewing the detailed overview of Coeptis Therapeutics Holdings's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coeptis Therapeutics Holdings Inc (NAS:COEP) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

105 Bradford Road, Suite 420, Wexford, PA, USA, 15090

Website

https://www.coeptistx.com

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio comprises multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Executives

Tara Desilva	director	105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
David Mehalick	director, 10 percent owner, officer: CEO and President	5000 TRESSDALE DRIVE, GIBSONIA PA 15044
Christopher P. Cochran	director	105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
Gene Salkind	director	1165 WRACK ROAD, MEADOWBROOK PA 19046
Daniel Alexander Yerace	director, officer: VP of Operations	402 SCHOMBURG COURT, CRANBERRY TOWNSHIP PA 16066
Chris Calise	director, 10 percent owner, officer: Chief Financial Officer	801 S. POINTE DRIVE SUITE TH-1, MIAMI BEACH FL 33139
Philippe Deschamps	director	105 BRADFORD RD, SUITE 420, WEXFORD PA 15090
Christine Elise Sheehy	officer: CFO and Secretary	206 TAMARACK DRIVE, MARS PA 16046
Harraden Circle Investments, Llc	10 percent owner	299 PARK AVE, 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Lp	10 percent owner	299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Llc	10 percent owner	299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Fortmiller Frederick Vincent Jr.	10 percent owner	151 LULL ROAD, NEW BOSTON NH 03070
Harraden Circle Investors, Lp	10 percent owner	299 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10171
Plc Barclays	10 percent owner	1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Paul J Glazer	10 percent owner	250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019